Shin Nippon Biomedical Laboratories, Ltd.
Stock Price Chart
2026/03/13 UpdatedPrice Trend
2026/03/13 UpdatedPrice & Trading Details
2026/03/13 UpdatedPRICE
TRADING
Analyst Recommendations 2 analysts
Updated 2026/03/01Earnings Calendar
Updated 2026/03/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2025/02/04 | ¥21.80 | ¥45.02 | +106.5% |
| 2024/08/05 | ¥24.97 | ¥2.93 | -88.3% |
| 2024/02/01 | ¥41.02 | ¥19.90 | -51.5% |
| 2023/11/07 | ¥26.97 | ¥38.26 | +41.9% |
Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
262.6K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
168.8K | 0.00% | |
|
WisdomTree Trust-WisdomTree Japan Hedged Equity Fund
|
137.6K | +45.61% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
|
75.0K | +21.75% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
65.8K | -36.55% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF
|
46.9K | +8.28% |
Dividend History
Updated 2026/03/15| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥50 | 0.0% |
| 2024 | ¥50 | 0.0% |
| 2023 | ¥50 | -16.7% |
| 2022 | ¥60 | +300.0% |
| 2021 | ¥15 | - |
Financial Performance
2026/03/15 UpdatedNo financial data available
Latest IR Information
-
FY2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)
Consolidated net sales for the third quarter of FY2026 amounted to JPY 21,195 million (4.7% decrease YoY), operating income was JPY 1,027 million (45.7% decrease YoY), and net income attributable to owners of parent for the quarter was JPY 2,270...
Read more -
Notice Regarding Revision of Full-Year Consolidated Earnings Forecast for the Fiscal Year Ending March 2026
The full-year sales forecast for the fiscal year ending March 2026 has been revised to 306.98 billion yen (7.7% decrease from previous forecast), operating income to 2.6 billion yen (26.8% decrease), and ordinary income to 5.353 billion yen (9.7% decrease).
Read more -
Fiscal Year Ending March 2026 Q3 Financial Results Presentation Materials
Cumulative Q3 sales for FY2026 were 21.19 billion yen, a 4.7% decrease YoY, with operating income of 1.02 billion yen, down 46.1% YoY. The full-year earnings forecast was revised downward, projecting sales of 30.69 billion yen and operating income of...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,590
Rating Score: 1.50 (Based on 2 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels. In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.
